4588.T JPX
Oncolys BioPharma Inc.
1W: -4.8%
1M: +28.6%
3M: +102.2%
YTD: +174.1%
1Y: +852.2%
3Y: +1024.1%
5Y: +267.8%
¥6,490.00 ($41.16)
+510.00 (+8.53%)
Weekly Expected Move ±14.7%
¥4216
¥5098
¥5980
¥6862
¥7744
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
-$1.9B
+3.9% ▲
Capital Expenditures
$3M
+14.4% ▲
5Y CAGR: +2.2%
Free Cash Flow
-$1.9B
+3.9% ▲
Dividends Paid
$0
+0.0% ▲
Buybacks
$1K
+100.0% ▲
Net Change in Cash
$1.5B
+71.8% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$1.6B | -$1.1B | -$1.9B | -$1.7B | -$2.1B |
| Depreciation & Amort. | $6M | $914K | $2M | $815K | $242K |
| Stock-Based Comp. | $209M | $58M | $10M | $19M | $0 |
| Change in Working Capital | -$533M | -$502M | $532M | -$369M | $40M |
| Other Non-Cash Items | $125M | -$128M | $58M | $13M | $77M |
| Operating Cash Flow | -$1.7B | -$1.7B | -$1.3B | -$2.0B | -$1.9B |
| — Investing Activities — | |||||
| Capital Expenditures | -$1M | -$1M | -$6M | -$4M | -$3M |
| Acquisitions (Net) | $0 | $0 | $136K | $0 | $0 |
| Investment Purchases | -$1K | -$1K | -$1K | -$1K | -$73K |
| Investment Sales | $486K | $0 | $0 | $0 | $0 |
| Other Investing | $10K | $21M | $159K | -$1M | -$4M |
| Investing Cash Flow | -$942K | $20M | -$5M | -$5M | -$8M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$25M | -$111M | -$99M | -$6M | -$5M |
| Stock Repurchased | -$36K | -$28K | $0 | -$5M | -$1K |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | $31M | -$3M | $18M | -$5M | -$1K |
| Financing Cash Flow | $3.1B | -$114M | $1.1B | $2.9B | $3.2B |
| Net Change in Cash | $1.4B | -$1.7B | -$178M | $878M | $1.5B |
| Cash End of Period | $3.2B | $1.5B | $1.3B | $2.2B | $3.7B |
| Free Cash Flow | -$1.7B | -$1.7B | -$1.3B | -$2.0B | -$1.9B |